Larvol Delta - Ankyra-Therapeutics-Announces-Phase-1-Clinical-Data-at-the-2025-AACR-Annual-Meeting-and-the-rst-patient-has-been-dosed-with-tolododekin-alfa-and-cemiplimab

tolododekin alfa (ANK-101) - Ankyra Therap

https://www.businesswire.com/news/home/20250428550798/en/Ankyra-Therapeutics-Announces-Phase-1-Clinical-Data-at-the-2025-AACR-Annual-Meeting-and-the-first-patient-has-been-dosed-with-tolododekin-alfa-and-cemiplimab

Apr 28, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next